- Home
- THAR vs PMVP Comparison
THAR vs PMVP Comparison
Compare THAR & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THAR | PMVP |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 68.9M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | THAR | PMVP |
|---|---|---|
| Price | $2.39 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | ★ 292.1K | 262.9K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.81 |
| 52 Week High | $9.08 | $1.84 |
Technical Indicators
Market Signals| Indicator | THAR | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 38.72 |
| Support Level | $2.36 | $1.14 |
| Resistance Level | $2.75 | $1.30 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 16.00 | 25.00 |
Price Performance
Historical ComparisonAbout THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.